Tyra Biosciences, Inc. (TYRA)

NASDAQ: TYRA · IEX Real-Time Price · USD
6.77
+0.31 (4.80%)
Nov 29, 2022 4:00 PM EDT - Market closed
4.8%
Market Cap 272.60M
Revenue (ttm) n/a
Net Income (ttm) -52.36M
Shares Out 42.00M
EPS (ttm) 0.70
PE Ratio 9.67
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 26,578
Open 6.66
Previous Close 6.46
Day's Range 6.52 - 6.87
52-Week Range 4.93 - 27.17
Beta n/a
Analysts Buy
Price Target 21.42 (+216.4%)
Earnings Date Nov 2, 2022

About TYRA

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company o... [Read more]

Industry Biotechnology
IPO Date Sep 15, 2021
Employees 25
Stock Exchange NASDAQ
Ticker Symbol TYRA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for TYRA stock is "Buy." The 12-month stock price forecast is 21.42, which is an increase of 216.40% from the latest price.

Price Target
$21.42
(216.40% upside)
Analyst Consensus: Buy
Stock Forecasts

News

How Much Upside is Left in Tyra Biosciences, Inc. (TYRA)? Wall Street Analysts Think 184%

The mean of analysts' price targets for Tyra Biosciences, Inc. (TYRA) points to an 184.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement...

5 days ago - Zacks Investment Research

Tyra Biosciences to Present at Upcoming Investor Conferences

CARLSBAD, Calif. , Nov. 10, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improv...

2 weeks ago - PRNewsWire

Wall Street Analysts Think Tyra Biosciences, Inc. (TYRA) Could Surge 179%: Read This Before Placing a Bet

The consensus price target hints at a 178.5% upside potential for Tyra Biosciences, Inc. (TYRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earn...

3 weeks ago - Zacks Investment Research

Tyra Biosciences Reports Third Quarter 2022 Financial Results and Highlights

-Pipeline on track; SURF301 study to be initiated; IND for TYRA-200 to be filed by year-end 2022- -Well-capitalized with cash and cash equivalents of $263.2 million as of Q3 2022- CARLSBAD, Calif. , Nov...

3 weeks ago - PRNewsWire

Tyra Biosciences Announces Planned Chief Financial Officer Transition

-Esther van den Boom to transition to an advisor at year-end 2022- -Alan Fuhrman to be named Chief Financial Officer- CARLSBAD, Calif. , Nov. 2, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA...

3 weeks ago - PRNewsWire

Tyra Biosciences to Present Preclinical Data on TYRA-200, an FGFR1/2/3 Inhibitor, at 34th EORTC-NCI-AACR Symposium on...

CARLSBAD, Calif. , Oct. 13, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improv...

1 month ago - PRNewsWire

Tyra Biosciences to Participate at September 2022 Investor Conferences

CARLSBAD, Calif. , Sept. 8, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improv...

2 months ago - PRNewsWire

Tyra Biosciences to Present Preclinical Data on TYRA-300, an FGFR3-selective Inhibitor, at ESMO 2022 Congress

CARLSBAD, Calif. , Sept. 5, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improv...

2 months ago - PRNewsWire

Tyra Biosciences Reports Second Quarter 2022 Financial Results and Highlights

-IND clearance received from FDA to proceed with SURF301 Study of TYRA-300- -Pipeline on track; IND for TYRA-200 to be filed in 2H 2022- -Well-capitalized with cash and cash equivalents of $275.1 millio...

3 months ago - PRNewsWire

Tyra Biosciences Reports First Quarter 2022 Financial Results and Highlights

-Pipeline on-track; INDs to be filed for TYRA-300 and TYRA-200 in 2022- -Well-capitalized with cash and cash equivalents of $292.5 million as of Q1 2022- CARLSBAD, Calif. , May 5, 2022 /PRNewswire/ -- T...

6 months ago - PRNewsWire

Tyra Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights

CARLSBAD, Calif., March 3, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve...

8 months ago - PRNewsWire

Tyra Biosciences to Participate in Cowen 42nd Annual Healthcare Conference

CARLSBAD, Calif., Feb. 22, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve...

9 months ago - PRNewsWire

Tyra Biosciences to Present at the 2021 Jefferies London Healthcare Conference

CARLSBAD, Calif., Nov. 10, 2021 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve...

1 year ago - PRNewsWire

Tyra Biosciences Reports Third Quarter 2021 Financial Results and Highlights

CARLSBAD, Calif., Nov. 3, 2021 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve ...

1 year ago - PRNewsWire